Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 15/20 | 0.69 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.69 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.69 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.69 |
| ▸ | ATR | Q13535 | 3/20 | 0.65 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13982352 | 0.92 | ATR (0.61) | PIK3CDPIK3CAPIK3CBPIK3CGATR | |
| SCHEMBL4788956 | 0.88 | ATR (0.61) | PIK3CDPIK3CAPIK3CBPIK3CGATR | |
| SCHEMBL4754666 | 0.87 | PIK3CA (0.65) | PIK3CDPIK3CAPIK3CBPIK3CGATR | |
| SCHEMBL13982550 | 0.86 | ATR (0.59) | PIK3CDPIK3CAPIK3CBPIK3CGATR | |
| SCHEMBL13982278 | 0.86 | ATR (0.58) | PIK3CDPIK3CAPIK3CBPIK3CGATR | |
| SCHEMBL4789276 | 0.85 | ATR (0.60) | PIK3CDPIK3CAPIK3CBPIK3CGATR | |
| SCHEMBL13982389 | 0.84 | ATR (0.59) | PIK3CDPIK3CAPIK3CBPIK3CGATR | |
| SCHEMBL13982546 | 0.84 | PIK3CA (0.55) | PIK3CDPIK3CAPIK3CBPIK3CGATR | |
| SCHEMBL393696 | 0.84 | PIK3CD (0.81) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2435066 | 0.83 | PIK3CA (0.64) | PIK3CDPIK3CAPIK3CBPIK3CGATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | claimed |
| WO-2012009452-A1 | THE ROLE OF P13K P110 DELTA SIGNALING IN RETROVIRAL INFECTION AND REPLICATION | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2012-01-19 | — | — | WO | claimed |
| WO-2008152387-A1 | QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-18 | — | — | WO | claimed |
| US-9949979-B2 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2018-04-24 | — | — | US | disclosed |
| US-9949979-B2 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2018-04-24 | — | — | US | disclosed |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | disclosed |
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | disclosed |
| US-20120184519-A1 | Compositions and Methods for Preventing or Treating Influenza Virus Infection | THE BABRAHAM INSTITUTE | 2012-07-19 | — | — | US | disclosed |
| WO-2012009452-A1 | THE ROLE OF P13K P110 DELTA SIGNALING IN RETROVIRAL INFECTION AND REPLICATION | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012009452-A1 | THE ROLE OF P13K P110 DELTA SIGNALING IN RETROVIRAL INFECTION AND REPLICATION | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2012-01-19 | — | — | WO | disclosed |
| US-20110135655-A1 | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication | PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; | 2011-06-09 | — | — | US | disclosed |
| WO-2008152387-A1 | QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135655-A1 | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication | PIK3R5, PIK3R4, PIK3R1 | PIK3CD 5/4885PIK3CA 10/4885PIK3CB 11/4885 |
| US-20120184519-A1 | Compositions and Methods for Preventing or Treating Influenza Virus Infection | PIK3R5, PIK3C2A, PIK3C2B | PIK3CD 6/4885PIK3CA 9/4885PIK3CB 10/4885 |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | TLR9, PIK3CD, PIK3R5 | PIK3CD 2/4885PIK3CA 8/4885PIK3CB 9/4885 |
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | PIK3R5, PIK3R4, PIK3R3 | PIK3CD 6/4885PIK3CA 10/4885PIK3CB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.